To update his groundbreaking handbook with the latest advances and perspectives, Charles M. Hansen has invited five renowned experts to share their work, theories, and practical applications involving HSPs. New discussions include a new statistical thermodynamics approach for confirming existing HSPs and how they fit into other thermodynamic theories for polymer solutions. Entirely new chapters examine the prediction of environmental stress cracking as well as absorption and diffusion in polymers. Highlighting recent findings on interactions with DNA, the treatment of biological materials also includes skin tissue, proteins, natural fibers, and cholesterol. The book also covers the latest applications of HSPs, such as ozone-safe “designer” solvents, protective clothing, drug delivery systems, and petroleum applications.
Presenting a comprehensive survey of the theoretical and practical aspects of HSPs, Hansen Solubility Parameters, Second Edition concludes with a detailed discussion on the necessary research, future directions, and potential applications for which HSPs can provide a useful means of prediction in areas such as biological materials, controlled release applications, nanotechnology, and self-assembly.
The first two sections of the book discuss the integration of cell cycle control pathways, opportunities for targeting, targets of inhibitors, and the evaluation of CDK inhibitors, exploring topics such as the in vivo function of CDKs in normal homeostasisand tumor development and the structural biology of CDKs. The third section examines the design, development, and chemistry of small molecule CDK inhibitors, with discussions ranging from the early-stage discovery of new chemical entities with a capacity to inhibit CDKs to late-stage compounds in clinical development. The final section assesses the current status of CDK inhibitors in clinical trials, the therapeutic deployment challenges of small molecule inhibitors, and the future development of CDK inhibitors as anticancer agents.
The field of drug development is at a critical point in terms of understanding the availability, advantages, and drawbacks of CDKs as therapeutic targets for small molecules. Providing the most up-to-date, in-depth coverage available in a single volume, Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents surveys the success of the agents developed thus far, the possibility of new routes to more selective inhibitors, and the growing appreciation of critical, therapeutic issues.